Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2006

View Archived Issues

Studies detail pharmacokinetics, efficacy of valopicitabine

LB-80380 safe and active in lamivudine-resistant hepatitis B infection

R-1626 safe and active in chronic hepatitis C

HCV-796 well tolerated in healthy subjects

Study reveals activity of CPG-10101 alone and with peginterferon in hepatitis C

Epratuzumab safe, effective in systemic lupus erythematosus

Pfizer presents novel orally active GnRH receptor antagonist

Genaera updates findings from phase II trials of Evizon

Positive preclinical findings for antiobesity drug candidate trodusquemine

tgAAC-09 studied for prevention of HIV in Zambia

AstraZeneca and Abraxis BioScience sign agreements for Abraxane and anesthetics

A.P. Pharma begins phase III study of APF-530

New phase II trial to evaluate INS-50589 Antiplatelet in CABG patients

Chronogen cleared to begin phase I/II study of CHGN-111 in Canada

Ilypsa grants Astellas Japanese rights to ILY-101

Oglemilast for asthma and COPD enters phase II

Pirfenidone begins phase III CAPACITY program in IPF

ImQuest inlicenses piperazine compounds from Samjin

PC-DAC:Exendin-4 data support once-weekly or less frequent dosing

ISIS-301012 reduces apoB-100 in preclinical and clinical studies

NBI-56418 shows robust treatment effect in endometriosis

Actemra filed for rheumatoid arthritis in Japan

Epogin approved for anemia in premature infants

European CHMP hands down positive opinion for Tysabri in MS

Approvable letter for Nuvigil

Myozyme receives FDA approval for Pompe disease

Research with PA-082 gives insight into the mechanism of action of partial PPARgamma agonists

Recent patents cover therapeutic agents for neurological disorders

Novel agents for treating diabetes disclosed in recent patents

Novel analgesic agents disclosed in recent Gruenenthal and Janssen patents